BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 38353266)

  • 1. Equivalent uniform RBE-weighted dose in eye plaque brachytherapy.
    Chvetsov AV
    Med Phys; 2024 Apr; 51(4):3093-3100. PubMed ID: 38353266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiobiology for eye plaque brachytherapy and evaluation of implant duration and radionuclide choice using an objective function.
    Gagne NL; Leonard KL; Rivard MJ
    Med Phys; 2012 Jun; 39(6):3332-42. PubMed ID: 22755715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dosimetry of (125)I and (103)Pd COMS eye plaques for intraocular tumors: report of Task Group 129 by the AAPM and ABS.
    Chiu-Tsao ST; Astrahan MA; Finger PT; Followill DS; Meigooni AS; Melhus CS; Mourtada F; Napolitano ME; Nath R; Rivard MJ; Rogers DW; Thomson RM
    Med Phys; 2012 Oct; 39(10):6161-84. PubMed ID: 23039655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A practical approach to estimating optic disc dose and macula dose without treatment planning in ocular brachytherapy using
    Lee YC; Lin SC; Kim Y
    Radiat Oncol; 2018 Nov; 13(1):221. PubMed ID: 30424782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dosimetric and radiobiologic comparison of
    Gorovets D; Gagne NL; Melhus CS
    Brachytherapy; 2017; 16(2):433-443. PubMed ID: 28161431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optic disc dose reduction in ocular brachytherapy using
    Lee YC; Lin SC; Kim Y
    J Appl Clin Med Phys; 2020 Sep; 21(9):57-70. PubMed ID: 32656945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BEDVH-A method for evaluating biologically effective dose volume histograms: application to eye plaque brachytherapy implants.
    Gagne NL; Leonard KL; Huber KE; Mignano JE; Duker JS; Laver NV; Rivard MJ
    Med Phys; 2012 Feb; 39(2):976-83. PubMed ID: 22320806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantifying the dosimetric influences of radiation coverage and brachytherapy implant placement uncertainty on eye plaque size selection.
    Gagne NL; Rivard MJ
    Brachytherapy; 2013; 12(5):508-20. PubMed ID: 23466357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Model-based dose calculations for COMS eye plaque brachytherapy using an anatomically realistic eye phantom.
    Lesperance M; Inglis-Whalen M; Thomson RM
    Med Phys; 2014 Feb; 41(2):021717. PubMed ID: 24506608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of 16 mm OSU-Nag and COMS eye plaques.
    Zhang H; Davidorf F; Qi Y
    J Appl Clin Med Phys; 2012 May; 13(3):3632. PubMed ID: 22584165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dosimetric comparison of circular Eye Physics and Collaborative Ocular Melanoma Study plaques to treat uveal melanoma.
    Dean MK; Studenski MT; Paez-Escamilla MA; Walter SD; Kwon D; Markoe AM; Harbour JW; Samuels SE
    Brachytherapy; 2019; 18(3):404-410. PubMed ID: 30797699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alternative dose for choroidal melanoma treated with an iodine-125 radioactive plaque: a single-institution retrospective study.
    Saconn PA; Gee CJ; Greven CM; McCoy TP; Ekstrand KE; Greven KM
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):844-8. PubMed ID: 20171804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delivered dose changes in COMS plaque-based ocular brachytherapy arising from vitrectomy with silicone oil replacement.
    Morrison H; Larocque MP; Menon G; Sloboda RS; Weis E
    Brachytherapy; 2019; 18(5):668-674. PubMed ID: 31272841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delivered dose uncertainty analysis at the tumor apex for ocular brachytherapy.
    Morrison H; Menon G; Larocque MP; Jans HS; Weis E; Sloboda RS
    Med Phys; 2016 Aug; 43(8):4891. PubMed ID: 27487906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monte Carlo dosimetry for 103Pd, 125I, and 131Cs ocular brachytherapy with various plaque models using an eye phantom.
    Lesperance M; Martinov M; Thomson RM
    Med Phys; 2014 Mar; 41(3):031706. PubMed ID: 24593710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ocular malignancies treated with iodine-125 low dose rate (LDR) brachytherapy at a single high-volume institution: A retrospective review.
    Richards Z; Nguyen ML; Kutteh M; Ahmad S; Henson C; Firestone B; Herman TS; Herman TF
    Med Dosim; 2022 Autumn; 47(3):273-279. PubMed ID: 35644778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prescribing to tumor apex in episcleral plaque iodine-125 brachytherapy for medium-sized choroidal melanoma: A single-institutional retrospective review.
    Vonk DT; Kim Y; Javid C; Gordon JD; Stea B
    Brachytherapy; 2015; 14(5):726-33. PubMed ID: 26051804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experimental validation of a new COMS-like 24 mm eye plaque for the treatment of large ocular melanoma tumors.
    McCauley Cutsinger S; Forsman R; Corner S; Deufel CL
    Brachytherapy; 2019; 18(6):890-897. PubMed ID: 31444131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A radiobiological model for the relative biological effectiveness of high-dose-rate 252Cf brachytherapy.
    Rivard MJ; Melhus CS; Zinkin HD; Stapleford LJ; Evans KE; Wazer DE; Odlozilíková A
    Radiat Res; 2005 Sep; 164(3):319-23. PubMed ID: 16137205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigating the dosimetric impact of seed location uncertainties in Collaborative Ocular Melanoma Study-based eye plaques.
    Johnson JE; Deufel CL; Furutani KM
    Brachytherapy; 2016; 15(5):661-8. PubMed ID: 27475484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.